Skip to content

Study · Animal study (in vivo) · mouse · 2025

3 results

Trofinetide Improves Cognitive Function in APP/PS1 Mice by Suppressing Inflammation and Apoptosis.

Chen M, Ning Y, Yang H, Jia J

Molecular neurobiology21 Nov 2025Cited by 2 (Europe PMC)

PMID41269410 (opens in a new tab)PMCIDPMC12638399 (opens in a new tab)DOI10.1007/s12035-025-05500-5 (opens in a new tab)PepBankPUB-41269410
Read at sourcePubMedAsk about this study
Jump to 3 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: CC BY-NC-ND. Results still quote short attributed sentences.

Results from this study3

3 results from studies that gave the peptide. No result from this study comes from people.

  1. 01AnimalAnimal study (in vivo)Efficacy outcome

    In APP/PS1 mice, trofinetide improved cognitive deficits and reduced amyloid plaques, microglial activation and neuronal loss.

    In plain wordsIn mice with APP/PS1 mutations, trofinetide improved cognition and reduced amyloid plaques, microglial activation, and neuron loss.

    Peptide
    Trofinetide
    Outcome
    MixedCognition, amyloid pathology, microglial activation and neuronal loss
    Study

    mousen: not reported in source

    APP/PS1 transgenic mice
    Outcome group
    Neuroprotection · Nervous system and cognition
    Studied dose
    Dose not stated · intraperitoneal · 2 monthsAs given in this study (mouse).

    Source sentences

    Summary
    Trofinetide significantly improved cognitive deficits, reduced Aβ plaque deposition, and decreased microglial activation and neuronal loss in APP/PS1 mice.
    1 context sentence
    Summary · context
    Six-month-old APP/PS1 transgenic mice received intraperitoneal trofinetide for 2 months.
  2. 02AnimalOther designMechanism

    In mouse and cell experiments, trofinetide increased PPAR-γ, reduced BACE1, inhibited NF-κB phosphorylation and caspase-3 activation, and restored Bax/Bcl-2 balance.

    In plain wordsIn mouse and cell experiments, trofinetide changed proteins involved in inflammation and cell death.

    Peptide
    Trofinetide
    Outcome
    MixedPPAR-γ, BACE1, NF-κB, caspase-3 and Bax/Bcl-2
    Study

    mousen: not reported in source

    Mouse and cell models; individual assay model not specified
    Outcome group
    Receptor activity and mechanism · Nervous system and cognition
    Studied dose
    Dose not stated

    Source sentences

    Summary
    Mechanistically, trofinetide upregulated PPAR-γ, reduced BACE1, suppressed NF-κB phosphorylation, inhibited caspase-3 activation, and restored Bax/Bcl-2 balance, alleviating neuroinflammation and apoptosis.
    2 context sentences
    Summary · context
    Six-month-old APP/PS1 transgenic mice received intraperitoneal trofinetide for 2 months.
    Summary · context
    In vitro, BV2 microglial cells and HT22 hippocampal neurons were treated with trofinetide against AβO-induced cytotoxicity. Western blot (WB) was used to analyze inflammation and apoptosis-related proteins.
  3. 03LabIn vitro (cells)Efficacy outcome

    In AβO-exposed cells, trofinetide reduced cytotoxicity, suppressed TNF-α, IL-6 and IL-1 in BV2 cells, and inhibited apoptosis in HT22 cells.

    In plain wordsIn cells exposed to AβO, trofinetide reduced cell toxicity, inflammatory cytokines in BV2 cells, and apoptosis in HT22 cells.

    Peptide
    Trofinetide
    Outcome
    DecreaseCytotoxicity, inflammatory cytokines and apoptosis
    Study

    mousen: not reported in source

    BV2 microglial cells and HT22 hippocampal neurons exposed to AβO
    Outcome group
    Neuroprotection · Nervous system and cognition
    Studied dose
    Dose not stated

    Source sentences

    Summary
    In vitro, it rescued AβO-induced cytotoxicity, suppressed inflammatory cytokines (TNF-α, IL-6, IL-1) in BV2 cells, and inhibited apoptosis in HT22 cells.
    1 context sentence
    Summary · context
    In vitro, BV2 microglial cells and HT22 hippocampal neurons were treated with trofinetide against AβO-induced cytotoxicity.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    28 Oct 2026, 02:03 UTC

    Study results updated

  2. Version 1

    27 Oct 2026, 16:37 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.